South Africa is at a critical crossroads in its fight against a rising tide of illicit, substandard, and falsified medicines. These pose a severe threat to public health. The influx is particularly alarming in relation to GLP-1 agonists, the popular class of medicines developed to treat type 2 diabetes and obesity. In response to this escalating crisis, the South African…